Mycobacterium bovis infection of an aortobifemoral bypass graft with Streptococcus intermedius superinfection after intravesical bacillus Calmette-Guérin immunotherapy for bladder cancer.
Abdominal mesh infection
Infectious aneurysm
Mycobacterium bovis
Streptococcus intermedius superinfection
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
11
06
2020
accepted:
29
07
2020
pubmed:
5
8
2020
medline:
26
11
2021
entrez:
5
8
2020
Statut:
ppublish
Résumé
The Bacillus Calmette-Guerin (BCG) is a life-attenuated form of Mycobacterium bovis widely used as immunotherapy for localized bladder cancer. Adverse reactions to intravesical BCG instillations are rare. We describe a 70-year-old man with a history of an aortobifemoral bypass graft, placement of a synthetic mesh for treatment of a ventral hernia and, most recently, superficial bladder cancer treated with BCG therapy. Ten months after his final intravesical BCG instillation, he complained of fever and asthenia. After 12 months of investigation, he was diagnosed with Mycobacterium bovis infection of his aortobifemoral bypass graft and abdominal mesh, with Streptococcus intermedius superinfection. The bypass graft was excised and replaced with an in situ arterial allograft, the abdominal mesh was removed, and treatment started with amoxicillin, isoniazid, rifampicin and ethambutol. Several additional vascular interventions were needed for allograft degradation, but 12 months after the final procedure, outcome was good. Among 35 cases of mycotic aneurysm reported after BCG therapy in the last 10 years, only one involved a vascular prosthesis. Surgical repair of such aneurysms using prosthetic grafts is commonly performed, associated with anti-mycobacterial treatment. Prognosis is poor with mortality of 14% (4/35) and a 26% rate of aneurysm recurrence under treatment (9/35).
Sections du résumé
BACKGROUND
BACKGROUND
The Bacillus Calmette-Guerin (BCG) is a life-attenuated form of Mycobacterium bovis widely used as immunotherapy for localized bladder cancer. Adverse reactions to intravesical BCG instillations are rare.
CASE
METHODS
We describe a 70-year-old man with a history of an aortobifemoral bypass graft, placement of a synthetic mesh for treatment of a ventral hernia and, most recently, superficial bladder cancer treated with BCG therapy. Ten months after his final intravesical BCG instillation, he complained of fever and asthenia. After 12 months of investigation, he was diagnosed with Mycobacterium bovis infection of his aortobifemoral bypass graft and abdominal mesh, with Streptococcus intermedius superinfection. The bypass graft was excised and replaced with an in situ arterial allograft, the abdominal mesh was removed, and treatment started with amoxicillin, isoniazid, rifampicin and ethambutol. Several additional vascular interventions were needed for allograft degradation, but 12 months after the final procedure, outcome was good.
DISCUSSION AND CONCLUSIONS
CONCLUSIONS
Among 35 cases of mycotic aneurysm reported after BCG therapy in the last 10 years, only one involved a vascular prosthesis. Surgical repair of such aneurysms using prosthetic grafts is commonly performed, associated with anti-mycobacterial treatment. Prognosis is poor with mortality of 14% (4/35) and a 26% rate of aneurysm recurrence under treatment (9/35).
Identifiants
pubmed: 32749595
doi: 10.1007/s15010-020-01495-4
pii: 10.1007/s15010-020-01495-4
doi:
Substances chimiques
BCG Vaccine
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
345-348Références
Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis. 2000;31:S91–S9393.
doi: 10.1086/314066
Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, et al. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014;93:236–54.
doi: 10.1097/MD.0000000000000119
Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am. 1992;19:565–72.
pubmed: 1636240
Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis. 2003;36:140–8.
doi: 10.1086/344908
Lareyre F, Reverso-Meinietti J, Carboni J, Gaudart A, Hassen-Khodja R, Raffort J. Mycotic Aortic aneurysm and infected aortic graft after intravesical bacillus Calmette-Guérin treatment for bladder cancer. Vasc Endovascular Surg. 2019;53:86–91.
doi: 10.1177/1538574418800128
Roylance A, Mosley J, Jameel M, Sylvan A, Walker V. Aorto-enteric fistula development secondary to mycotic abdominal aortic aneurysm following intravesical bacillus Calmette-Guerin (BCG) treatment for transitional cell carcinoma of the bladder. Int J Surg Case Rep. 2013;4:88–90.
doi: 10.1016/j.ijscr.2012.09.009
Hui DS, Stoeckel DA, Kaufman EE, Jacobs DL. Massive hemoptysis from an aortobronchial fistula secondary to BCG-related mycotic thoracic aortic aneurysm. Ann Thorac Surg. 2016;101:350–2.
doi: 10.1016/j.athoracsur.2015.03.053
Shakir F, Dang V, Bronze MS, Liu C, Machado L. Mycobacterium bovis infection of an axillary-femoral bypass graft after intravesical bacille Calmette-Guérin immunotherapy for bladder cancer. Am J Med Sci. 2009;337:63–4.
doi: 10.1097/01.MAJ.0000308884.50320.8a
Coscas R, Arlet J-B, Belhomme D, Fabiani J-N, Pouchot J. Multiple mycotic aneurysms due to Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy. J Vasc Surg. 2009;50:1185–90.
doi: 10.1016/j.jvs.2009.06.004
Nguyen MT, Berger RL, Hicks SC, et al. Comparison of outcomes of synthetic mesh vs suture repair of elective primary ventral herniorrhaphy: a systematic review and meta-analysis. JAMA Surg. 2014;149:415–21.
doi: 10.1001/jamasurg.2013.5014
Kaoutzanis C, Leichtle SW, Mouawad NJ, et al. Risk factors for postoperative wound infections and prolonged hospitalization after ventral/incisional hernia repair. Hernia. 2015;19:113–23.
doi: 10.1007/s10029-013-1155-y